Return to study ST000954 main page
MB Sample ID: SA057159
| Local Sample ID: | 13765281 |
| Subject ID: | SU000993 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 11-67 yo |
| Weight Or Weight Range: | 32-194 kg |
| Height Or Height Range: | 141-388 cm |
| Gender: | Male and female |
| Human Race: | 47% white, 53% african american |
| Human Ethnicity: | 95% not Hispanic |
| Human Trial Type: | Open-label, prospective cohort study |
| Human Lifestyle Factors: | NA |
| Human Medications: | fluticasone (was not the intervention in this project, all participants received this drug for 2 weeks prior to sample collection) |
| Human Prescription Otc: | prescription |
| Human Smoking Status: | 9% current, 20% former |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR001007 |
| Treatment Summary: | All subjects will be treated with at least 110 mg of fluticasone propionate once or twice daily (Flovent® MDI) during the 2-week treatment period. |
| Treatment Protocol ID: | NCT00708227 |
| Treatment Protocol Comments: | Note: Fluticasone was not the intervention in this project; all study participants received this drug for 2 weeks prior to blood collection for the sample being used for the metabolomic analysis. However, participants did receive different doses of fluticasone in order to have them remain on the same dose that they were on prior to study entry. This was to ensure that their asthma remained stable at the end of the 2 week treatment with fluticasone. |
| Treatment Compound: | fluticasone |
| Treatment Route: | nebulizer; inhaled |
| Treatment Dose: | 110 mcg, 220 mcg, 440 mcg, 880 mcg |
| Treatment Doseduration: | daily |
